Illumina Launches TruPath Genome, a $395 Whole-Genome Workflow Targeting Rare Genetic Disease
核心洞察
Illumina has launched TruPath Genome (搜索), a whole-genome sequencing workflow that eliminates traditional library prep and delivers 16 genomes per day in about 10 minutes of hands-on time.
The platform fully phases up to 98% of genes and extends accurate variant calling into difficult-to-map 'dark regions' of the genome using on-flow-cell library preparation and DRAGEN (搜索) algorithms.
Data presented at AGBT showed TruPath Genome (搜索) resolving challenging loci including the SMN1 (搜索)/SMN2 (搜索) region in spinal muscular atrophy (搜索) and genes linked to inherited adrenal disorders.
Illumina, Inc. (NASDAQ: ILMN) announced the launch of TruPath™ Genome, a whole-genome sequencing workflow the company describes as setting a new standard for high-quality, comprehensive genomic insight in genetic disease. The launch was unveiled during the Gold Sponsor Workshop at the Advances in Genome Biology and Technology (AGBT) annual meeting in Orlando, with supporting data presented at the same meeting. The product was previously referred to as "constellation mapped read technology."
According to Illumina, TruPath Genome (搜索) delivers accuracy and resolution even across so-called "dark regions" of the genome, providing researchers with a more complete picture of genomic alterations implicated in genetic disease. The workflow eliminates traditional library preparation, generating 16 whole genomes per day in about 10 minutes of hands-on time — nearly double the throughput of competing long-read methods, and with fewer errors, the company said.
On-Flow-Cell Library Prep and Phasing Performance
TruPath Genome (搜索) leverages novel on-flow-cell library preparation with patterned flow cell technology and advanced informatics to add long-distance insights for comprehensive variant detection. DRAGEN (搜索)™ algorithms tuned to incorporate proximity information from TruPath flow cells improve read alignment and variant calling, extending Illumina high-quality reads to difficult-to-map regions, variant phasing, structural variants, short tandem repeats (STR), and clinically relevant paralogous genes. Illumina states that TruPath Genome fully phases up to 98% of genes.
"With TruPath Genome (搜索), we are pushing the boundaries of genomics and setting a new standard for genetic and rare disease research," said Steve Barnard, PhD, chief technology officer of Illumina. "In rare disease, you're often looking for a variant needle in a genomic haystack—and comprehensiveness, accuracy, and confidence matter. This technology unlocks rapid answers to shed light on the genomic drivers of genetic disease with an ease that was never thought possible."
The company positions the product as a cost-effective whole-genome workflow solution at a $395 USD list price, including all consumables and analysis, at an industry standard depth of at least 30x coverage with a single-use flow cell — a specification Illumina notes is critical in clinical research.
AGBT Data in Rare Disease Samples
Data presented at AGBT and in previous publications illustrate how TruPath Genome (搜索) is already being applied to challenging genetic diseases, including spinal muscular atrophy (搜索), kidney disease, and complex adrenal disorders.
Researchers at University Medical Center Utrecht presented data evaluating TruPath Genome (搜索) in challenging rare disease samples, with particular focus on long-range phasing performance required to support non-invasive prenatal diagnostic (NIPD) assays, as well as resolution of difficult genomic regions and complex structural variants.
"TruPath Genome (搜索) enabled us to consolidate multiple analyses into a single, easy-to-implement whole-genome assay," said Marcel Nelen, PhD, head of the Genome Diagnostic Laboratory at UMC Utrecht. "Despite the simplicity of the workflow, we achieved megabase-scale phasing, full resolution of clinically relevant genes, and improved interpretation of difficult regions—even a particularly challenging case in the notoriously complex SMN1 (搜索)/SMN2 (搜索) region—as well as complex structural variants. This represents an important step toward a single assay capable of addressing many rare disease research questions without additional orthogonal testing."
At the recent Festival of Genomics & Biodata in London, researchers from the University of Exeter shared data from their pilot of TruPath Genome (搜索), which found that the technology resolved highly complex genomic regions, including a gene known to be associated with inherited adrenal disorders. Whereas current short-read whole-genome sequencing requires parental samples to identify compound heterozygotes, TruPath Genome offers a single-sample path to these insights, improving coverage for samples processed without parental data.
"TruPath Genome (搜索) opens up a future where every patient affected by a rare genetic condition can receive rapid comprehensive whole-genome testing to end diagnostic odysseys and identify possible precision treatments," said Emma Baple, PhD, professor of Genomic Medicine at the University of Exeter and medical lead for the NHS England Rapid Genome Sequencing Service for Critically Unwell Children. "In Exeter, we have been privileged to evaluate the TruPath technology and seen the potential to change the lives of affected children and their families. We are eager to see how this innovation evolves, as these types of solutions will transform how rare conditions are diagnosed."
Early Adopters and Evaluation Experience
Broad Clinical Labs (搜索) is among the first to adopt TruPath Genome (搜索), which will make the technology available to its collaborators in rare disease research.
"TruPath means a more comprehensive genome to drive our research," said Sean Hofherr, PhD, FACMG, chief of clinical strategy and product development, Broad Clinical Labs (搜索). "This technology delivers an impressive ability to interrogate even the most challenging variants in the genome, all in a stunningly simple workflow. And, being able to run it on the NovaSeq X Plus is attractive."
More than 30 early access customers have been piloting the technology over the past 16 months, including GeneDx (搜索), Rady Children's Hospital (搜索), and Baylor College of Medicine. Baylor College of Medicine recently published a pre-print on the technology in medRxiv.
In a separate interview published by News-Medical, Nelen described his laboratory's early evaluation of the technology, noting that no data output was returned to customers and that the technology was not used in clinical testing during that evaluation. He identified on-flow-cell library preparation as the most significant innovation, alongside the ability to use native DNA for proximity-based phasing.
"One of the earliest samples we ran was a spinal muscular atrophy (搜索) (SMA) family. Previously, we had been analyzing this locus for six months using long-read technologies. TruPath's first run produced clean, accurate data," Nelen said. He added that long-read methods necessitate DNA shearing and size optimization, whereas TruPath uses native DNA with phased blocks that are considerably larger — sometimes megabases. "I have never seen that level of phasing before," he said.
Nelen said phasing is the primary benefit of the data, as it can be difficult with short reads and often requires obtaining parental samples. He stated that TruPath significantly reduces that need while offering major benefits over both PacBio and ONT in terms of phasing size and workflow ease. Asked about adoption impact, he said there is potential to retire several of the laboratory's current workflows — somewhere between 15 and 20 today, a number of which require specialized skills or older technologies — consolidating many into a simplified, more generic workflow, with an almost seamless transition because it runs on the same instruments and uses the DRAGEN (搜索) environment.
He also noted that the technology could help eliminate or significantly reduce the need for parental samples in recessive research cases, enhance structural variant detection, and facilitate reliable phasing, potentially replacing separate assays such as inversion tests for genes like Factor VIII (搜索). Early experiments for the laboratory's non-invasive prenatal project were described as extremely encouraging.
Illumina's press release includes forward-looking statements noting risks and uncertainties, including challenges inherent in developing and launching new products and services, reliance on third-party suppliers for critical components, the ability to manufacture robust instrumentation and consumables and develop reliable software solutions, and customer acceptance and adoption of newly launched or updated products.